

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM744277

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Theratechnologies Inc.		07/27/2022	Corporation: CANADA
RECEIVING PARTY DATA			
Name:	U.S. Bank Trust Company, National Association		
Street Address:	One Federal Street		
City:	Boston		
State/Country:	MASSACHUSETTS		
Postal Code:	02110		
Entity Type:	National Banking Association: UNITED STATES		
PROPERTY NUMBERS Total: 8			
Property Type	Number	Word Mark	
Registration Number:	3962100	EGRIFTA	
Serial Number:	97285560	EGRIFTA MDV	
Registration Number:	6077575	EGRIFTA SV	
Serial Number:	97285545	EGRIFTA WR	
Serial Number:	90119125	SORT1+ TECHNOLOGY	
Registration Number:	5748166	THERA PATIENT SUPPORT	
Registration Number:	6242335	T THERA TECHNOLOGIES	
Serial Number:	90182407	V=V	
CORRESPONDENCE DATA			
Fax Number:	2125046666		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	212-504-6000		
Email:	jennifer.chick@cwt.com		
Correspondent Name:	Cadwalader, Wickersham & Taft LLP		
Address Line 1:	200 Liberty Street		
Address Line 4:	New York, NEW YORK 10281		
ATTORNEY DOCKET NUMBER:	90545.007		
NAME OF SUBMITTER:	Jennifer A. Chick		

CH \$215.00 3962100

SIGNATURE:	/Jennifer A. Chick/
DATE SIGNED:	07/28/2022
Total Attachments: 32 source=TMs_Titan_IP Security Agreement_2022July27_executed#page1.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page2.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page3.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page4.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page5.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page6.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page7.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page8.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page9.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page10.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page11.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page12.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page13.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page14.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page15.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page16.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page17.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page18.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page19.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page20.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page21.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page22.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page23.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page24.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page25.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page26.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page27.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page28.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page29.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page30.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page31.tif source=TMs_Titan_IP Security Agreement_2022July27_executed#page32.tif	

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of July 27, 2022 (as amended, supplemented, amended and restated or otherwise modified from time to time, this “Agreement”), is by and among Theratechnologies Inc., a corporation governed by the Business Corporations Act (Quebec) (the “Borrower”), Theratechnologies Europe Limited, a private company limited by shares incorporated under the laws of Ireland having company number 612162 (the “Irish Guarantor”), Theratechnologies U.S., Inc., a Delaware corporation (“Theratechnologies U.S.”), Theratechnologies Intercontinental Inc., a corporation governed by the Business Corporations Act (Quebec) (“Theratechnologies Intercontinental”), Theratechnologies Europe Inc., a corporation governed by the Business Corporations Act (Quebec) (“Theratechnologies Europe”), and Pharma-G Inc., a corporation governed by the Business Corporations Act (Quebec) (and together with the Borrower, the Irish Guarantor, Theratechnologies U.S., Theratechnologies Intercontinental and Theratechnologies Europe, each a “Grantor” and, collectively with each other Person who now or hereafter is a party to this Agreement, the “Grantors”) in favor of U.S. Bank Trust Company, National Association (“Collateral Agent”), not individually, but solely in its capacity as collateral agent (together with its successors and assigns in such capacity, the “Secured Party”) for the benefit of the Agents and the Lenders (as hereinafter defined).

RECITALS:

WHEREAS, pursuant to that certain Credit Agreement, dated as of July 20, 2022 (as amended, supplemented, amended and restated or otherwise modified from time to time, the “Credit Agreement”), by and among the Borrower, the financial institutions from time to time party to the Credit Agreement as lenders (collectively, with their permitted successors and assignees, the “Lenders”), U.S. Bank Trust Company, National Association, in its capacity as administrative agent (in such capacity, the “Administrative Agent”, and together with the Collateral Agent, the “Agents”) and the Secured Party, the Lenders have agreed to provide certain financial accommodations to the Borrower; and

WHEREAS, the Lenders are willing to extend financial accommodations to the Borrower as provided for in the Credit Agreement, but only upon the condition, among others, that the Grantors shall have executed and delivered to the Secured Party, for its benefit and the benefit of the Agents and the Lenders, this Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

Section 1. Defined Terms; Rules of Construction.

- (a) Capitalized terms used in this Agreement but not otherwise defined herein have the meanings given to them in the Credit Agreement, and if not defined therein, in the U.S. Security Agreement (as defined in the Credit Agreement, the “U.S. Security Agreement”).
- (b) When used herein the following terms shall have the following meanings:

“Copyrights” shall have the meaning provided thereto in the U.S. Security Agreement.

“Copyright Licenses” means all agreements pursuant to which any Grantor is licensor or licensee, granting any right under any Copyright, including but not limited to, rights to manufacture, reproduce, display, distribute, perform, modify or otherwise exploit, and sell materials embodying or derived from, any copyrighted work.

“Intellectual Property” shall have the meaning provided thereto in the U.S. Security Agreement.

“Obligations” shall have the meaning provided thereto in the Credit Agreement.

“PTO” means the United States Patent and Trademark Office and any successor office or agency.

“Patents” shall have the meaning provided thereto in the U.S. Security Agreement.

“Patent Licenses” means all agreements pursuant to which any Grantor is licensor or licensee, granting any right to manufacture, have made, import, use, or sell any invention covered in whole or in part by a Patent.

“Proceeds” shall have the meaning provided thereto in the U.S. Security Agreement.

“Products” shall have the meaning provided thereto in the Credit Agreement.

“Trademarks” shall have the meaning provided thereto in the U.S. Security Agreement.

“Trademark Licenses” mean all agreements pursuant to which any Grantor is licensor or licensee, granting any right to use a Trademark.

“UCC” shall have the meaning provided thereto in the U.S. Security Agreement.

- (c) All Schedules, Addenda, Annexes and Exhibits hereto or expressly identified to this Agreement are incorporated herein by reference and taken together with this Agreement constitute but a single agreement. The words “herein”, “hereof” and “hereunder” or other words of similar import refer to this Agreement as a whole, including the Exhibits, Addenda, Annexes and Schedules thereto, as the same may be from time to time amended, modified, restated or supplemented, and not to any particular section, subsection or clause contained in this Agreement. Wherever from the context it appears appropriate, each term stated in either the singular or plural shall include the singular and the plural, and pronouns stated in the masculine, feminine or neuter gender shall include the masculine, the feminine and the neuter. The term “or” is not exclusive. The term “including” (or any form thereof) shall not be limiting or exclusive. All references to statutes and related regulations shall include any amendments of same and any successor statutes and regulations. All references in this Agreement or in the Schedules, Addenda, Annexes and Exhibits to this Agreement to sections, schedules, disclosure schedules, exhibits, and attachments shall refer to the corresponding sections, schedules, disclosure

schedules, exhibits, and attachments of or to this Agreement. All references to any instruments or agreements, including references to any of this Agreement, the Credit Agreement or the other Loan Documents shall include any and all modifications or amendments thereto and any and all extensions or renewals thereof.

- (d) The parties acknowledge that each party and its counsel have reviewed this Agreement and that the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement or any amendments, schedules or exhibits thereto.

Section 2. Grant of Security Interest in Intellectual Property Collateral. To secure the prompt payment to the Lenders of the Obligations of the Grantors now or hereafter existing from time to time, each Grantor hereby pledges and grants to the Secured Party, for the benefit of the Agents and the Lenders, a continuing security interest in and Lien upon all of such Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Collateral"):

- (a) Trademarks and Trademark Licenses to which it is a party, including those referred to on Schedule I hereto;
- (b) Patents and Patent Licenses to which it is a party, including those referred to on Schedule II hereto;
- (c) Copyrights and Copyright Licenses to which it is a party, including those referred to on Schedule III hereto;
- (d) Intellectual Property not covered by the foregoing, including those referred to on Schedule IV hereto;
- (e) Renewals, reissues, continuations, divisions, or extensions of any of the foregoing;
- (f) Rights to sue third parties for past, present or future infringement, dilution, misappropriation, or other violation of rights in any Intellectual Property, including injury to the goodwill associated with any Trademark, and all causes of action for the same; and
- (g) All products and Proceeds of all or any of the foregoing, tort claims and all claims and other rights to payment including (i) insurance claims against third parties for loss of, damage to, or destruction of, the foregoing Collateral and (ii) payments due or to become due under licenses of any or all of the foregoing and Proceeds payable under, or unearned premiums with respect to policies of insurance in whatever form; provided, however, that the Collateral shall not include or extend to any Excluded Property (provided that, for the avoidance of doubt, if any Excluded Property ceases to be Excluded Property, at such time, it shall automatically be included in the Collateral).

Section 3. Representations and Warranties. Each Grantor represents and warrants to the Secured Party, the Agents and the Lenders, in addition to the representations and warranties in the Credit Agreement and the other Loan Documents, that:

- (a) such Grantor has been using statutory notice of registration in connection with its use of registered Trademarks, proper marking practices in connection with the use of Patents, and appropriate notice of copyright in connection with the publication of copyrighted material;
- (b) such Grantor has taken all actions necessary to ensure that all licensees of Trademarks owned by such Grantor use consistent standards of quality as directed by such Grantor in connection with its licensed products and services; and
- (c) this Agreement, together with the U.S. Security Agreement, is effective to create a valid security interest in favor of the Secured Party, for its benefit and the benefit of the Lenders, in all of such Grantor's Collateral. Upon (i) the filing of all appropriate UCC-1 financing statements (with respect to each Grantor's (A) Patents, (B) Trademarks and (C) any Copyrights of such Grantor not registered with the United States Copyright Office), (ii) the filing of this Agreement in the PTO (with respect to the Trademarks set forth on Schedule I hereto that are registered with the PTO and the Patents set forth on Schedule II hereto that have been granted by the PTO), and (iii) the filing of this Agreement in the United States Copyright Office (with respect to the Copyrights set forth on Schedule III hereto registered with the United States Copyright Office), such security interest will be enforceable and all action necessary to perfect the Secured Party's Lien on such Grantor's Patents, Trademarks, and Copyrights, shall have been taken.

Section 4. Covenants. Each Grantor covenants and agrees with the Secured Party for the benefit of the Agents and the Lenders, from and after the date of this Agreement, and in addition to the covenants in the Credit Agreement and the other Loan Documents, that:

- (a) Such Grantor shall notify the Secured Party promptly in writing if it knows or has reason to know that any application or registration relating to any material Intellectual Property owned by such Grantor has or may become abandoned, dedicated to the public, placed in the public domain or otherwise invalidated or unenforceable. Such Grantor shall further notify the Secured Party promptly in writing of any adverse determination or decision in any proceeding and the institution of any proceeding challenging such Grantor before the PTO, the United States Copyright Office, or any similar agency of the United States, any State, or other country or political subdivision thereof, any internet domain registry or other registry, or any court, regarding such Grantor's ownership of or right to use, register, keep and/or maintain any material Intellectual Property. Such Grantor shall be free to prosecute and maintain its Intellectual Property in the ordinary course of business in a commercially reasonable manner, and, notwithstanding the foregoing, shall not be required to report preliminary or initial determinations, unless and until made final (with no further right to appeal or proceed available or otherwise taken by Grantor), by the PTO, the United States Copyright Office, or any similar agency of

the United States, any State, or other country or political subdivision thereof, any internet domain registry or other registry, or any court, regarding such Grantor's ownership of or right to use, register, keep and/or maintain any Intellectual Property;

- (b) Such Grantor shall comply with and take such actions required by Section 6.3(d) of the Credit Agreement. Any expenses incurred in connection with the Grantors' obligations under this Section 4(b) shall be borne by the Grantors. Except for any such items that a Grantor reasonably believes (using prudent industry customs and practices) are no longer necessary for the on-going operations of its business, the Grantors shall not abandon any material right to file a patent, trademark or service mark application, or abandon any material pending patent, trademark or service mark application or any other material Copyright, Patent, Trademark or other Intellectual Property of such Grantor without the prior written consent of the Secured Party (at the written direction of the Required Lenders), which consent shall not be unreasonably withheld;
- (c) In the event that any Intellectual Property owned by or exclusively licensed to such Grantor is infringed, diluted, misappropriated, or otherwise violated by a third party, such Grantor shall notify the Secured Party promptly in writing after such Grantor learns thereof and shall promptly take, to the extent legally or contractually permitted, all commercially reasonable actions to stop the same and enforce its rights in such Intellectual Property and to recover all damages therefor, including, but not limited to, the initiation of a suit for injunctive relief and damages where reasonable and cost effective to do so and shall take such other actions as are commercially reasonable, or as the Secured Party (at the written direction of the Required Lenders) shall deem appropriate in its good faith exercise of its commercially reasonable discretion under the circumstances to protect such Grantor's rights in such Intellectual Property;
- (d) Such Grantor shall use appropriate statutory notice of registration in connection with its use of registered Trademarks, proper marking practices in connection with the use of Patents, appropriate notice of copyright in connection with the publication of copyrighted materials, and other legends or markings applicable to other Intellectual Property;
- (e) Such Grantor shall take all commercially reasonable steps necessary to protect the secrecy of all trade secrets material to its business; and
- (f) In the event any Grantor, (i) either directly or through any agent, employee, licensee or designee, files an application for the registration of any Patent, Trademark or Copyright with the PTO, the United States Copyright Office or any similar office or agency, (ii) obtains rights to any new patentable inventions, any registered Copyrights or any Patents or Trademarks, or (iii) becomes entitled to the benefit of any registered Copyrights or any Patents or Trademarks or any improvement on any Patent, the provisions of this Agreement shall automatically apply thereto and such Grantor shall give to the Secured Party written notice thereof by delivery of

an updated Schedule III, IV, V and/or VI to the U.S. Security Agreement, as applicable, in accordance with Section 2(e) of the U.S. Security Agreement. The Grantors hereby authorize the Secured Party to modify this Agreement by amending Schedules I, II, III and IV hereto, as applicable, to include any such registered Copyrights or any such Patents and Trademarks, or other Intellectual Property and to execute and deliver a supplement hereto (in form and substance satisfactory to the Secured Party and the Required Lenders) to evidence the Secured Party's lien on any such Patent, Trademark, Copyright or other Intellectual Property, and the general intangibles of such Grantor relating thereto or represented thereby.

Section 5. Credit Agreement and U.S. Security Agreement. The security interests granted pursuant to this Agreement are granted in conjunction with the security interests granted by each Grantor to the Secured Party, for its benefit and the benefit of the Agents and the Lenders pursuant to the U.S. Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Secured Party with respect to the Collateral made and granted herein are more fully set forth in the Credit Agreement and the U.S. Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. Any rights and remedies set forth herein are without prejudice to, and in addition to, those set forth in the Credit Agreement and the U.S. Security Agreement. In the event any provisions contained herein expressly conflict with any provisions in the Credit Agreement or the U.S. Security Agreement covering Intellectual Property, the provisions herein shall control.

The Secured Party, subject to the provisions of Section 9 of the Credit Agreement, including receipt of indemnification or security satisfactory to Secured Party, shall act (or omit to act) at the written direction of the Required Lenders under any provision of this Agreement requiring the Secured Party to take action or to omit from taking action (other than ordinary administration) or to exercise discretion.

Section 6. Reinstatement. This Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against any Grantor for liquidation or reorganization, should any Grantor become insolvent or make an assignment for the benefit of any creditor or creditors or should a receiver or trustee be appointed for all or any significant part of such Grantor's assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether as a "voidable preference," "fraudulent conveyance," or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

Section 7. Indemnification. Each Grantor assumes all responsibility and liability arising from the use of the Intellectual Property and Grantors, jointly and severally, hereby indemnify and hold the Secured Party, the Agents and the Lenders and each of the officers, directors, employees, Affiliates, controlling persons, advisors and agents of the Secured Party, the Agents and the Lenders harmless from and against any claim, suit, loss, damage or expense (including reasonable attorneys' fees and expenses, including, but not limited to, the costs of enforcing the

indemnification provisions set forth in this Section 7) arising out of any Grantor's operations of its business from the use of the Intellectual Property, except to the extent any such claim, suit, loss, damage or expense results from the Secured Party's, Agent's or Lender's own gross negligence or willful misconduct, in each case as determined by a court of competent jurisdiction by final and nonappealable judgment. In any suit, proceeding or action brought by the Secured Party under any Patent License, Trademark License, or Copyright License for any sum owing thereunder, or to enforce any provisions of such License, Grantors will, jointly and severally, indemnify and keep the Secured Party, the Agents and their officers, directors, employees, Affiliates, controlling persons, advisors and agents harmless from and against all expense, loss or damage suffered by reason of any defense, set off, counterclaim, recoupment or reduction or liability whatsoever of the obligee thereunder, arising out of a breach of any Grantor of any obligation thereunder or arising out of any other agreement, indebtedness or liability at any time owing to or in favor of such obligee or its successors from any Grantor, except to the extent any such expense, loss or damage results from the Secured Party's own gross negligence or willful misconduct, in each case as determined by a court of competent jurisdiction in a final, non-appealable determination, and all such obligations of Grantors shall be and remain enforceable against and only against Grantors and shall not be enforceable against the Secured Party, any Agent or any Lender.

Section 8. Notices. All notices hereunder shall be in writing (including facsimile transmission) and shall be sent to the applicable party (i) in the case of the Grantors, in care of the Borrower, at the address of the Borrower set forth in the Credit Agreement, and (ii) in the case of the Secured Party, at the address of the Collateral Agent set forth in the Credit Agreement, or, in each case, at such other address as such party may, by written notice received by the other parties, have designated as its address for such purpose. All notices and other communications given to any party hereto in accordance with the provisions of this Agreement shall be deemed to have been given on the date of receipt if received during the recipient's normal business hours. Any party hereto may change its address or facsimile number or email address for notices and other communications hereunder by written notice to the other parties hereto.

Section 9. Termination of this Agreement. Subject to Section 6 hereof, this Agreement shall terminate upon the Payment in Full in cash of all Obligations.

Section 10. Governing Law. THIS AGREEMENT SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES (OTHER THAN SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW).

Section 11. Counterparts; Electronic Signatures. This Agreement may be executed in any number of counterparts and by the different parties hereto on separate counterparts and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Agreement. Receipt by facsimile or electronic transmission (including PDF) of any executed signature page to this Agreement shall constitute effective delivery of such signature page. The words "delivery," "execute," "execution," "signed," "signature," and words of like import in this Agreement or any other document executed in connection herewith shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Secured Party, or the keeping of records in

electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act; provided that notwithstanding anything contained herein to the contrary, the Secured Party is under no obligation to agree to accept electronic signatures in any form or in any format unless expressly agreed to by the Secured Party pursuant to procedures approved by it; provided, further, without limiting the foregoing, upon the reasonable request of the Secured Party, any electronic signature shall be promptly followed by such manually executed counterpart. All notices, approvals, consents, requests and any communications hereunder must be in writing; provided that any communication sent to the Secured Party hereunder must be in the form of a document that is signed manually or by way of a digital signature provided by DocuSign (or such other digital signature provider as specified in writing to the Secured Party by an authorized representative), in English. The Grantors each agree to assume all risks arising out of the use of digital signatures and electronic methods to submit communications to Secured Party, the Agents or the Lenders, including without limitation the risk of the Secured Party acting on unauthorized instructions and the risk of interception and misuse by third parties. For the avoidance of doubt, the authorization under this paragraph may include, without limitation, use or acceptance by the Secured Party of a manually signed paper document, amendment, approval, consent, information, notice, certificate, request, statement, disclosure or authorization related to this Agreement (each a “Communication”) which has been converted into electronic form (such as scanned into PDF format), or an electronically signed Communication converted into another format, for transmission, delivery and/or retention. Each Grantor hereby acknowledges the receipt of a copy of this Agreement. The Secured Party may, on behalf of each Grantor, create a microfilm or optical disk or other electronic image of this Agreement. The Secured Party may store the electronic image of this Agreement in its electronic form and then destroy the paper original as part of the Secured Party’s normal business practices, with the electronic image deemed to be an original and of the same legal effect, validity and enforceability as the paper originals.

Section 12. Companies Registration Office of Ireland. By its execution of this Agreement, the Irish Guarantor irrevocably and unconditionally authorises any and each solicitor from time to time in the Irish law firm acting for Secured Party, the Agents and the Lenders (“Lenders Solicitors”) to:

(a) sign or complete (whether electronically or otherwise) on behalf of the Irish Guarantor all required security related registration forms required to be delivered to the Companies Registration Office (“CRO”) in connection with this Agreement;

(b) file (whether electronically or otherwise) each such registration form with the CRO; and

(c) include an email address for a solicitor in the Lenders Solicitors in each such registration form for the purposes of receiving any certificate of registration of charge electronically from the CRO.

In giving this authorisation, the Irish Guarantor agrees and acknowledges that:

(d) no solicitor/client relationship exists between the Lenders Solicitors (or any solicitor at that law firm) and the Irish Guarantor;

(e) it is the Irish Guarantor's responsibility to comply with the procedures set out in Sections 409(3) and (4) of the Irish Companies Act (without prejudice to Section 410(2) thereof); and


(f) the Lenders Solicitors have no liability or responsibility to the Irish Guarantor for any failure to comply with the terms of this authorisation where the Lenders Solicitors have taken all reasonably practicable steps to comply with the applicable requirements and such failure is due to anything outside the reasonable control of the Lenders Solicitors.

[Signature Pages Follow]


IN WITNESS WHEREOF, each Grantor has executed this Intellectual Property Security Agreement as of the date first written above.

GRANTORS:


THERATECHNOLOGIES, INC.

By: 
Name: Philippe Dubuc
Title: Senior Vice President and Chief Financial Officer

THERATECHNOLOGIES EUROPE LIMITED

By: 
Name: Philippe Dubuc
Title: Attorney

THERATECHNOLOGIES U.S., INC.

By: 
Name: Philippe Dubuc
Title: Vice President and Chief Financial Officer


THERATECHNOLOGIES
INTERCONTINENTAL INC.

By: 
Name: Philippe Dubuc
Title: Chief Financial Officer

THERATECHNOLOGIES EUROPE INC.

By: 
Name: Philippe Dubuc
Title: Chief Financial Officer

PHARMA-G INC.

By: 
Name: Philippe Dubuc
Title: Chief Financial Officer

[Signature Page to Intellectual Property Security Agreement]

TRADEMARK
REEL: 007805 FRAME: 0026

ACCEPTED and ACKNOWLEDGED by:

U.S. BANK TRUST COMPANY, NATIONAL
ASSOCIATION, as Collateral Agent

By:  _____

Name: Alison D.B. Nadeau

Title: Vice President

Schedule I

Trademarks and Trademark Licenses

TRADEMARKS

Trademark	Appl. #	Reg. #	Status	Country of Reg.	Appl. DI	Reg. DI	Goods and Services	Owner	Security Interest Information
TROGARZ O & design	AL/T/2017/ 449	18289	Registered	Albania	05/05 /2017	05/05 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
EGRIFTA	3,067,846	2,501,214	Registered	Argentina	02/17 /2011	05/04 /2012	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	1,213,363	1,213,363	Registered	Australia	12/04 /2007	12/04 /2007	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	84486	84486	Registered	Bahrain	11/24 /2010	11/24 /2010	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.

EGRIFTA	902513486	902513486	Registered	Brazil	04/19 /2010	01/15 /2013	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	1,350,032	922,456	Registered	Canada	06/04 /2007	12/04 /2015	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	1,705,737	907,719	Registered	Canada	12/04 /2014	07/03 /2015	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA HC	1,930,011	1,122,161	Registered	Canada	11/12 /2018	03/07 /2022	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA MDV	2,159,096	N/A	Pending	Canada	01/10 /2022	N/A	Pharmaceutical preparations for the treatment of lipodystrophy, obesity,	Theratechnologies Inc.	None.

							wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.		
EGRIFTA SUPPORT	1,718,011	984,908	Registered	Canada	03/05 /2015	11/15 /2017	Pharmaceutical preparations for the treatment of lipodystrophy; Providing medical assistance and medical information in the field of lipodystrophy.	Theratechnologies Inc.	None.
EGRIFTA SV	1,930,012	1,111,749	Registered	Canada	11/12 /2018	10/18 /2021	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA WR	2,159,097	N/A	Pending	Canada	01/10 /2022	N/A	Pharmaceutical preparations for the treatment of lipodystrophy; Providing medical assistance and medical information in the field of lipodystrophy.	Theratechnologies Inc.	None.
MYBALCO	1,797,690	1,048,917	Registered	Canada	08/26 /2016	08/14 /2019	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	Theratechnologies Inc.	None.
SORT1+ TECHNOLOGY	2,043,407	N/A	Pending	Canada	07/31 /2020	N/A	Pharmaceutical preparations for the treatment of cancer.	Theratechnologies Inc.	None.

SORTI+ TECHNOL OGY	2,187,924	N/A	Pending	Canada	05/26 /2022	N/A	Cancer treatment targeting sortilin receptors.	Theratechnologi es Inc.	None.
THE RA PATIENT SUPPORT	1,840,109	1,053,664	Registere d	Canada	05/31 /2017	09/11 /2019	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the treatment of HIV/AIDS; providing medical information in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat,	Theratechnologi es Inc.	None.

							adipose tissue, ectopic fat, liver fat and for the treatment of HIV/AIDS" and related health conditions.		
TROGARZ O	1,797,688	1,048,911	Registered	Canada	08/26 /2016	08/14 /2019	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
TROGARZ O & design	1,805,648	1,048,514	Registered	Canada	10/20 /2016	08/12 /2019	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
V=V Logo	2050457	N/A	Pending	Canada	09/09 /2020	N/A	Providing information related to HIV.	Theratechnologies Inc.	None.
ZIBALVO	1,797,689	1,048,907	Registered	Canada	08/26 /2016	08/14 /2019	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	Theratechnologies Inc.	None.
EGRIFTA	11-020011	431,680	Registered	Colombia	02/18 /2011	08/29 /2011	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	6,329,049	006329049	Registered	Community Mark	10/05 /2007	09/04 /2008	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.

EGRIFTA HC	17987332	17987332	Registered	Community Mark	11/20/2018	05/0/2019	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA MDV	018642099		Published	Community Mark	01/20/2022	N/A	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.	Theratechnologies Inc.	None.
EGRIFTA SV	17987325	17987325	Registered	Community Mark	11/20/2018	05/01/2019	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA WR	018642098	N/A	Published	Community Mark	01/20/2022	N/A	Pharmaceutical preparations for the treatment of lipodystrophy; Providing medical assistance and medical information in the field of lipodystrophy.	Theratechnologies Inc.	None.

SEQUS	764.316	000764316	Registered	Community Mark	03/09 /1998	11/18 /1999	Computer software for use in evaluating the quality of care and health services.	Theratechnologies Inc.	None.
SORTI+ TECHNOLOGY	018294851	18294851	Registered	Community Mark	08/24 /2020	12/15 /2020	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
THERA PATIENT SUPPORT	016825432	016825432	Registered	Community Mark	06/08 /2017	10/06 /2017	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the treatment of HIV/AIDS; 44: Providing medical assistance namely instructions on drug administration and assessment of insurance coverage in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the	Theratechnologies Inc.	None.

							treatment of HIV/AIDS; providing medical information in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the treatment of HIV/AIDS		
THERA technologies & design	016699092	016699092	Registered	Community Mark	05/10 /2017	09/11 /2017	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat and liver fat; pharmaceutical preparations for the prevention and treatment of HIV-1 infection; Providing medical assistance namely instructions on drug administration and assessment of insurance coverage in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat,	Theratechnologies Inc.	None.

						liver fat and for the treatment of HIV/AIDS; providing medical information in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the treatment of HIV/AIDS" and related health conditions.			
TROGARZ O & design	016555252	016555252	Registered	Community Mark	04/04 /2017	08/01 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
V=V Logo	018309181	018309181	Registered	Community Mark	09/16 /2020	N/A	Providing information related to HIV.	Theratechnologies Inc.	None.
ZELFENCE	017509829	017509829	Registered	Community Mark	11/21 /2017	11/21 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
TROGARZ O & design	V0104216	V0104216	Registered	Iceland	03/31 /2017	04/30 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
ZELFENCE	V0106950	V0106950	Registered	Iceland	11/21 /2017	11/30 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
EGRIFTA	229,343	229,343	Registered	Israel	04/21 /2010	04/21 /2010	Pharmaceutical preparations for the treatment of	Theratechnologies Inc.	None.

							lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.		
TROGARZ O & design	293226	293226	Registered	Israel	04/04 /2017	04/04 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
ZELFENCE	300309	300309	Registered	Israel	11/21 /2017	11/21 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
EGRIFTA	120782/2007	5,132,430	Registered	Japan	12/04 /2007	04/25 /2008	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
SORT1+ TECHNOL OGY	2021- 010033	6425630	Registered	Japan	01/29 /2021	08/05 /2021	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	117781	117781	Registered	Jordan	11/22 /2010	11/22 /2010	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive	Theratechnologies Inc.	None.

						impairment and traumatic brain injury.			
						Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.	
EGRIFTA	40-2011-0050881	40-0948014	Registered	Korea (South)	09/19/2011	01/09/2013			
EGRIFTA	242	133,037	Registered	Lebanon	01/10/2011	01/13/2011	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
TROGARZ O & design	2017-250	18038	Registered	Liechtenstein	04/07/2017	04/07/2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
ZELFENCE	2017-1003	18243	Registered	Liechtenstein	11/21/2017	11/21/2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
EGRIFTA	1,082,294	1,182,919	Registered	Mexico	04/16/2010	04/16/2010	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	201004144	256,722	Registered	Norway	04/20/2010	09/13/2010	Pharmaceutical preparations for the	Theratechnologies Inc.	None.

						treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.			
TROGARZ O & design	201704317	294037	Registered	Norway	04/05 /2017	04/05 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
ZELFENCE	201715657	297,007	Registered	Norway	11/21 /2017	11/21 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
EGRIFTA	65595	65595	Registered	Oman	11/22 /2010	11/22 /2010	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	65244	65244	Registered	Qatar	12/05 /2010	12/05 /2010	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
TROGARZ O & design	201771235 3	656148	Registered	Russia	04/03 /2017	04/03 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
ZELFENCE	201774894 2	675,482	Registered	Russia	11/21 /2017	11/21 /2017	Pharmaceutical preparations for the	TaiMed Biologics Inc.	None.

							prevention and treatment of HIV-1 infection.		
							Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	163143	1351/42	Registered	Saudi Arabia	12/26 /2010	04/15 /2012	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	2011/03480	2011/03480	Registered	South Africa	02/18 /2011	02/18 /2011	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
							Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA	53769/2010	599,810	Registered	Switzerland	04/16 /2010	04/16 /2010	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
TROGARZ O & design	54190/2017	704,246	Registered	Switzerland	04/03 /2017	04/03 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
ZELFENCE	64537/2017	714,720	Registered	Switzerland	11/21 /2017	11/21 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
EGRIFTA	12069	61930	Registered	Syria	11/29 /2010	11/29 /2010	Pharmaceutical preparations for the	Theratechnologies Inc.	None.

								treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.		
EGRIFTA	100047606	01521687	Registered	Taiwan	09/16/2011	06/16/2012	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.	
EGRIFTA	821,096	KOR366625	Registered	Thailand	09/20/2011	09/20/2011	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.	
EGRIFTA	2010-26791	2010-26791	Registered	Turkey	04/22/2010	04/22/2010	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.			
TROGARZ O & design	2017/31255	201731255	Registered	Turkey	04/06/2017	04/06/2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.	

EGRIFTA	6,329,049	UK0090632 9049	Registered	United Kingdom	10/05/2007	10/05/2007	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA HC	17987332	UK0091798 7332	Registered	United Kingdom	11/20/2018	11/20/2018	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
EGRIFTA SV	17987325	UK0091798 7325	Registered	United Kingdom	11/20/2018	11/20/2018	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
Thera Patient Support	016825432	UK0091682 5432	Registered	United Kingdom	06/08/2017	06/08/2017	Providing medical assistance and medical information in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the treatment of HIV/AIDS.	Theratechnologies Inc.	None.

THERA technologies & design	016699092	UK0091669 9092	Registered	United Kingdom	05/10 /2017	05/10 /2017	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat and liver fat; pharmaceutical preparations for the prevention and treatment of HIV-1 infection; Providing medical assistance namely instructions on drug administration and assessment of insurance coverage in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the treatment of HIV/AIDS; providing medical information in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the	Theratechnologies Inc.	None.
-----------------------------	-----------	----------------	------------	----------------	-------------	-------------	---	------------------------	-------

Schedules to IP Security Agreement

								treatment of HIV/AIDS" and related health conditions.		
TROGARZ O & design	016555252	UK0091655 5252	Registered	United Kingdom	04/04 /2017	04/04 /2017	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.	
EGRIFTA	77/343,258	3,962,100	Registered	United States	12/04 /2007	05/17 /2011	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.	
EGRIFTA MDV	97/285,560	N/A	Pending	United States	02/25 /2022	N/A	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.	Theratechnologies Inc.	None.	
EGRIFTA SV	88/200,431	6,077,575	Registered	United States	11/20 /2018	06/16 /2020	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.	

EGRIFTA WR	97/285,545	N/A	Pending	United States	02/25 /2022	N/A	Pharmaceutical preparations for the treatment of lipodystrophy; Providing medical assistance and medical information in the field of lipodystrophy.	Theratechnologies Inc.	None.
SORT1+ TECHNOLOGY	90/119,125	N/A	Examined	United States	08/17 /2020	N/A	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.
THERA PATIENT SUPPORT	87/470,202	5,748,166	Registered	United States	05/31 /2017	05/14 /2019	Providing medical assistance and medical information in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the treatment of HIV/AIDS.	Theratechnologies Inc.	None.
THERA technologies & design	87/442,965	6,242,335	Registered	United States	05/09 /2017	01/12 /2021	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat and liver fat.	Theratechnologies Inc.	None.

							pharmaceutical preparations for the prevention and treatment of HIV-1 infection; Providing medical assistance namely instructions on drug administration and assessment of insurance coverage in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the treatment of HIV/AIDS; providing medical information in the field of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment, traumatic brain injury, visceral adipose tissue, ectopic fat, liver fat and for the treatment of HIV/AIDS" and related health conditions.		
TROGARZ O	87/168,448	5,551,395	Registered	United States	09/12/2016	08/28/2018	Pharmaceutical preparations for the prevention and treatment of HIV-1 infection.	TaiMed Biologics Inc.	None.
TROGARZ O & design	87/216,382	5,566,378	Registered	United States	10/26/2016	09/18/2018	Pharmaceutical preparations for the	TaiMed Biologics Inc.	None.

V=V Logo	90182407	N/A	Examined	United States	09/15/2020	N/A	Providing information related to HIV.	Theratechnologies Inc.	None.										
EGRIFTA	149,439	149,439	Registered	UAE Arab Emirates	11/14/2010	11/14/2010	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.										
EGRIFTA	02885-2011	P-321,926	Registered	Venezuela	02/24/2011	10/19/2012	Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury.	Theratechnologies Inc.	None.										

TRADEMARK

REEL: 007805 FRAME: 0048

RECORDED: 07/28/2022

Schedules to IP Security Agreement